Supported by

Catalogue of collaboration profiles

back to list
Company

ImmunoSolv Limited

Street
Little France Crescent
ZIP Code
EH16 4SB
City
Edinburgh
Country
United Kingdom


Company Profile:
ImmunoSolv is a vibrant, young biotechnology company born out of world-class science at the University of Edinburgh and University of Aberdeen, Scotland, UK. We specialize in the development of enabling technologies aimed at improving the quality of all animal cells in vitro – including cells for therapy – through detection and removal of dead cells.

Efficacy of cell therapy products is directly linked to three key parameters – (i) retaining the correct phenotype to maximise potency, (ii) maintaining the highest possible viability to maximise effective dose and (iii) extending longevity of product to allow shipping from cleanroom to patient. Sub-optimal conditions with regard to either of these three key parameters, may lead to a substantial decrease in therapeutic potential. Currently no products are commercially available to ensure these three key parameters are optimised. Studies conducted by ImmunoSolv (looking at removal of dead and dying cells from culture media) demonstrated that our lead product ‘DeadCert’ has a proven ability to increase cell viability and longevity, coupled with potential to aid retention of phenotype.

Based at our Aberdeen facility - ImmunoSolv is also able to offer a bespoke antibody engineering service to industry. ImmunoSolv has a dedicated team of world-class immunobiologists and antibody engineers capable of helping client-companies maximise rapid product development in this important market.

Profiltitel

Antibody enginering services

What we offer:
ImmunoSolv offers a breadth of services across all areas of therapeutic protein development. Custom monoclonal antibody generation utilises complimentary technologies: (i) via rodent hybridomas, and (ii) in vitro display technology (such as phage display).

What are we looking for:
Potential clients and collaborators.

Collaboration sought:
  • Manufacturing Agreement
  • Commercial Agreement


Responsible

Michael Leek

Business Development Director
Profiltitel

Optimisation of cell therapy products

What we offer:
An innovative GMP-compliant technology formulated to optimise the viability, purity and longevity of cell therapeutic products.

What are we looking for:
Collaborations with companies active in (i) cell therapy and (ii) bioprocessing.

Collaboration sought:
  • Research & Development
  • Technical Co-operation
  • Manufacturing Agreement
  • Licence
  • Commercial Agreement


Responsible

Michael Leek

Business Development Director
back to list

Participants

Enterprise Europe ScotlandAboleo LtdAccuro BiologicsAlliance BootsBeta TechnologyBitWiseFW Medical LLPInnova Partnerships LtdInterface-The knowledge connection for businessMarks and Clerk LLPMcClure Naismith LLPThe Medical Device Company LtdQuantics Consulting LtdScottish Health InnovationsPharmalinksSistemic LtdStrathclyde Institute of Medical DevicesSynthetic Nanomachines LtdTissue SolutionsUniversity of AberdeenEllis IP LtdPharmacells LtdCeltic CatalystsPharmaceutical eConsultingWeatherologyControlled TherapeuticsSphere Fluidics LimitedHighland Clinical Research FacilityMoorfields PharmaceuticalsEdinburgh Science Trianglebeocarta LtdRostiShore DesignPomBioTech GmbHIMG Innovations-Management  GmbH/ Enterprise Europe NetworkThe Eurotactics ConsultancyIBA GmbHSGS Life Science ServicesOnorach  ClinicalWideblueEnterprise Europe YorkshireAptuit ConsultingMosaigen/Endeavour CapitalEscubed LtdEulysis Ltd.Raumedic LtdCatalent Pharma SolutionsEscubed LtdUniversity of Aberdeen Research and InnovationSPRI - Basque Enterprise Europe NetworkLicentia LtdTake The WindRoslin CellabMoredun ScientificEnterprise Europe East of EnglandAvantiCell ScienceXeroshield Ltd.ImmunoSolv LimitedLeoben Research LimitedPRAXI / HELP-FORWARD Network &The Hellenic BioClusterEMBIO Diagnostics Ltd


© 2010 ConVerve GmbH | all rights reserved